2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023-Reference-Cited by-同舟云学术

2019 ASCCP Risk-Based Management Consensus Guidelines: Updates Through 2023

Published:2024-01 Issue:1 Volume:28 Page:3-6
ISSN:1526-0976
Container-title:Journal of Lower Genital Tract Disease
language:en
Short-container-title:J Low Genit Tract Dis

Author:

Perkins Rebecca B.¹,Guido Richard S.²,Castle Philip E.³,Chelmow David⁴,Einstein Mark H.⁵,Garcia Francisco⁶,Huh Warner K.⁷,Kim Jane J.⁸,Moscicki Anna-Barbara⁹,Nayar Ritu¹⁰,Saraiya Mona¹¹,Sawaya George F.¹²,Wentzensen Nicolas³,Schiffman Mark³,

Affiliation:

1. Boston University School of Medicine/Boston Medical Center, Boston, MA

2. University of Pittsburgh/Magee-Women's Hospital, Pittsburgh, PA

3. National Cancer Institute, Bethesda, MD

4. Virginia Commonwealth University School of Medicine, Richmond, VA

5. Rutgers, New Jersey Medical School, Newark, NJ

6. Pima County Health & Community Services, Tucson, AZ

7. UAB School of Medicine, Birmingham, AL

8. Harvard T.H. Chan School of Public Health, Boston, MA

9. University of California, Los Angeles, Los Angeles, CA

10. Northwestern University, Feinberg School of Medicine-Northwestern Memorial Hospital, Chicago, IL

11. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA

12. University of California, San Francisco; San Francisco, CA; Division of Cancer Epidemiology and Genetics; and Division of Cancer Prevention, National Cancer Institute, Bethesda, MD

Abstract

Abstract This Research Letter summarizes all updates to the 2019 Guidelines through September 2023, including: endorsement of the 2021 Opportunistic Infections guidelines for HIV+ or immunosuppressed patients; clarification of use of human papillomavirus testing alone for patients undergoing observation for cervical intraepithelial neoplasia 2; revision of unsatisfactory cytology management; clarification that 2012 guidelines should be followed for patients aged 25 years and older screened with cytology only; management of patients for whom colposcopy was recommended but not completed; clarification that after treatment for cervical intraepithelial neoplasia 2+, 3 negative human papillomavirus tests or cotests at 6, 18, and 30 months are recommended before the patient can return to a 3-year testing interval; and clarification of postcolposcopy management of minimally abnormal results.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Obstetrics and Gynecology,General Medicine

Reference9 articles.

1. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors;J Low Genit Tract Dis,2020

2. Erratum: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors;J Low Genit Tract Dis,2021

3. Response to Letter to the Editor regarding: 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors;J Low Genit Tract Dis,2020

4. Risk-based cervical consensus guidelines: methods to determine management if less than 5 years of data are available;J Low Genit Tract Dis,2022

5. Does the interval between Papanicolaou tests influence the quality of cytology?;Cancer,2005